Florian Lordick: Can ATM Deficiency Become an Actionable Biomarker?
Florian Lordick/LinkedIn

Florian Lordick: Can ATM Deficiency Become an Actionable Biomarker?

Florian Lordick, Oncologist, Professor of Medicine at University of Leipzig, Head of Medical Oncology, Director of the Comprehensive Cancer Center Central, Germany, shared on LinkedIn:

“Excellent science grows through excellent partnerships.

Congratulations to Zuzanna Trybala on this outstanding publication and on an impressive piece of scientific work!

The paper tackles one of the most exciting questions in precision oncology for upper gastrointestinal cancers: Can ATM deficiency become an actionable biomarker? Our article comprehensively reviews the biology of ATM, its clinical relevance in oesophageal and gastric cancer, and the therapeutic opportunities arising from defects in the DNA damage response.

Importantly, our review identifies ATR inhibition as the most promising therapeutic strategy for ATM-deficient tumours while emphasizing that ATM alterations should not simply be considered ‘BRCA-like.’ We also highlight the next steps needed to translate these insights into clinical practice.

This publication is another great example of the fruitful collaboration between the Masaryk Memorial Cancer Institute (MMCI) Brno and the Comprehensive Cancer Center Central Germany (Leipzig–Jena) Leipzig University Universitätsklinikum Leipzig AöR. It demonstrates how international cooperation, shared expertise, and the exchange of talented young scientists can accelerate innovation in cancer research.

We are particularly proud that this work has been fostered within the PRESSURE Consortium, supported by the European Union’s Horizon Europe programme (HE MSCA DN, SE and COFUND, Grant No. 101119464) and led by Maarten Bijlsma. Investing in young researchers and cross-border collaboration is one of the best ways to shape the future of oncology.

Congratulations again, Zuzanna, on this excellent achievement! It has been a pleasure to contribute to this work, and I am looking forward to many more exciting discoveries emerging from this strong partnership between Brno and Leipzig–Jena.”

Title: Exploiting the weak link: Ataxia-Telangiectasia Mutated dysfunction in oesophagogastric tumours

Authors: Zuzanna Trybala, Giulia Costella, Kristina Bednarova, Łukasz Arcimowicz, Achim Aigner, Florian Lordick, Radka Lordick Obermannová, Petr Müller

Read the Full Article.

Florian Lordick: Can ATM Deficiency Become an Actionable Biomarker?

Other articles featuring Florian Lordick on OncoDaily.